Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

BFRI : 1.1100 (+3.74%)
BFRIW : 0.0856 (+0.59%)
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic...

BFRI : 1.1100 (+3.74%)
Biofrontera Inc. Completes $4.2 Million Private Placement of Senior Secured Convertible Note

Biofrontera completes a $4.2 million secured convertible note private placement to support operations and growth initiatives.Quiver AI SummaryBiofrontera Inc. has announced the completion of a $4.2 million...

BFRI : 1.1100 (+3.74%)
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

BFRI : 1.1100 (+3.74%)
BFRIW : 0.0856 (+0.59%)
Biofrontera Inc. Reports Third Quarter 2024 Financial Results Amid Hurricane Impact and Positive Product Developments

Biofrontera reported Q3 2024 revenues of $9 million, affected by Hurricane Milton, with notable Ameluz sales growth and FDA approval.Quiver AI SummaryBiofrontera Inc. reported total revenues of $9.0 million...

BFRI : 1.1100 (+3.74%)
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

BFRI : 1.1100 (+3.74%)
BFRIW : 0.0856 (+0.59%)
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRI : 1.1100 (+3.74%)
BFRIW : 0.0856 (+0.59%)
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRI : 1.1100 (+3.74%)
BFRIW : 0.0856 (+0.59%)
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

BFRI : 1.1100 (+3.74%)
BFRIW : 0.0856 (+0.59%)
Global Laser Therapy Devices Billion Dollar Market Thriving on Growing Demand

Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary –  The laser therapy market has been having a very health growth trend in recent years and is expected to continue through...

PIXY : 6.53 (-14.30%)
EW : 75.65 (-0.36%)
BFRI : 1.1100 (+3.74%)
LITE : 84.36 (-1.55%)
CUTR : 0.3280 (+2.85%)

Barchart Exclusives

4 Highest-Rated Dividend Aristocrats To Buy Now
These three highly-rated companies offer a combination of growth and at least 25 years of increasing dividends. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar